-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on Trevi Therapeutics, Lowers Price Target to $23

Benzinga·05/06/2026 11:19:53
Listen to the news
Needham analyst Serge Belanger maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and lowers the price target from $24 to $23.